Founded in 2013, BioAscent is a leading provider of integrated drug discovery services. Our expert scientists provide medicinal chemistry, in vitro biosciences and compound management services from our base in the former Organon / Merck Sharpe and Dohme (MSD) R&D site in Newhouse, Scotland, and via Compound Cloud we offer access to an IP-free compound library in assay ready format.
Our drug discovery services include de novo assay development, target analysis and bespoke screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry and data management (>100 biochemical and biophysical assays established for drug discovery projects, >50 hit validation/characterisation projects, and >25 hit-to-lead campaigns since 2013). Our team of expert scientists has experience of successfully working from assay development through to preclinical and clinical candidates across all biological target classes and major therapeutic indications.
We currently hold and manage over 1 million compounds for our customers in our €20 million facility, storing and managing customer libraries ranging in size from a few thousand to a few hundred thousand compounds in both liquid and solid formats. We constantly receive and aggregate new compounds from our customers and their chemistry CRO partners, and ship in the assay-ready format of choice to their screening laboratories
Via our Compound Cloud service, we provide rapid access to an IP-free library of ~125,000 lead like compounds in screening-ready format. Our expertise in cherry picking, reformatting, shipping and data management have allowed us to deliver over 80,000 screening plates globally to our customers and their partner testing laboratories since 2013.
We are located in modern purpose-built laboratories on a single site, the former Organon / Merck Sharpe and Dohme (MSD) research & development facility, based within the BioCity Scotland campus at Newhouse, Scotland, UK.
Domainex is a fully integrated drug discovery service company based near Cambridge, UK serving pharmaceutical, biotechnology, academic and patient foundations globally. Our expertise and commitment to providing high quality services has resulted in a strong success record in drug discovery, delivering an average one candidate drug every year for the past six years.
Domainex’s highly experienced molecular, protein, structural and assay biologists plus medicinal, computational and analytical chemists can be leveraged through our CRO services. Domainex’s focus is on providing highly efficient and well considered scientific solutions to enable successful drug discovery programmes against a wide range of drug targets.
Domainex offers a range of services including:
• Medicinal chemistry (including SBDD)
• FragmentBuilder (Domainex’s proprietary fragment screening platform)
• Computational Chemistry (including LeadBuilder Domainex’s proprietary virtual screening platform)
• Assay Development and Screening (biochemical, biophysical and cell assays)
• iPSC and immune cell biology
• Protein Production
• CDH (Domainex’s proprietary technology which enables the rapid identification of stable, soluble protein domains)
• Analytical chemistry
• X-ray crystallography services
Whether your project is at an early stage of drug discovery or has already identified chemical matter, our processes have been shown to result in a 30% time-saving compared to industry standards and use less resource, allowing prudent management of your own budget.
Red Glead Discovery performs integrated drug discovery. Focusing on small molecules and peptides, our drug discovery platform ranges from medicinal chemistry and synthesis to ADME and biology. The services are supported by computational Chemistry as well as advanced MS and NMR analysis, also available as stand-alone services. Fragment-based drug discovery is an import area of expertise where we offer access for clients and partners to our proprietary technique WAC (Weak Affinity Chromatography) in combination with other FBDD techniques and methods.
Our project management skills and cross-disciplinary capabilities make us a preferred partner for clients and partners that want to develop compounds with high potential to become successful drugs.
Besides our CRO business, we also perform research project collaborations with various biotech and academic partners. RGD was founded in 2011 by former Astra Zeneca employees and merged with Pepticon in 2014. RGD has today over 45 co-workers. Please visit our web site or contact us directly to know more about us.
UNDER CONSTRUCTION - ATG is a synthetic biology and biotech company. We combine proprietary analytical and synthetic bioinformatics tools and expertise with systems for the design, assembly and expression of multi-gene and multi-peptide constructs.
Products and services for drug discovery, industrial and medical biotechnology, molecular diagnostics, and bioengineering.
* Multi-gene recombineering and expression systems for E.coli, insect and mammalian cells (Toggle, MultiLabel)
* Tailor-made expression systems for other (micro)organisms based on a modular assembly strategy (Toggle)
* Proprietary multi-peptide library design tool + biosystems-based multi-peptide library construction and expression system (PepID) for rationally designed bio-peptide libraries. Assess, identify (map) and verify peptide epitopes, antibodies, or protein-protein-interactions in diagnostics and therapy.
* Gene intelligence solution EvoMAG for multi-parametric complex gene / (artificial) combinatorial gene cluster design as well as formal and operational optimization and moldeling of genes, genetic elements and expression cassettes for diverse target/production organisms (e.g. for functional enzyme optimization, metabolic engineering, signal pathway analysis, etc.)
* Gene synthesis of genes and gene clusters
* Plasmid production and purification
* State-of-the-art computational biology solutions / analysis for immunomics, metabolomics, gene expression analysis in your target organism of choice, etc.
Aurora Fine Chemicals is a privately held company that was founded in 1990. As a chemicals R&D supplier we offer chemicals for R&D, drug discovery service, compound libraries and custom synthesis. We have one of the largest collections of 18.1 mln. chemicals available in stock and our docking software delivers hits/leads of very high quality in short time.
Our staff consists of highly qualified individuals with Bsc, Msc and Ph.D. degrees in chemistry, as well as excellent laboratory technicians. In our Molecular Modeling Group are professionals specializing in computational drug design. They possess many years experience of working in the chemistry of heterocycles, carbohydrates, nucleosides and elemental organic compounds. Aurora has significant expertise in synthesis of all types R&D chemicals for drug discovery like small molecules, natural products and peptides. Parallel synthesis with well-designed, targeted and fragment-based libraries is the favored approach to lead optimization. Rational design is the strategy for projects driven by structural biology, such as enzyme inhibitors or protein interactions.
We own a large library of 18.1 million stocked compounds for R&D. Our substances are used in many research labs all over the world. We offer structures for biochemical and chemical research. Our products are applied in pharmaceutical development, diagnosis, and in chemical production.
Several laboratories for synthesis with modern equipment such as reactors, autoclaves, thermostats and hydrogenation equipment are available.
Intermediates and final products are analyzed by GC, HPLC, IR, NMR, MS, elemental analysis, atom-absorption analysis and crystallographical methods.
The main advantage of Aurora's own software is the quality of the underlying physical models. Aurora's software derives molecular properties from first principles based on direct models using advanced quantum mechanical analysis of molecular interactions and thermodynamics.